Diagnostic Study for Differentiating Functional From Organic Diseases in Patients With Lower GIT Symptoms
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSohag University
About this trial
The study is intended to find a new trusted, cost-effective biomarker for differentiating irritable bowel syndrome from inflammatory bowel disease to decrease the use of unnecessary invasive methods in patients with irritable bowel syndrome
Eligibility criteria
Qualifiers
Adults (≥18 years) presenting with chronic lower gastrointestinal symptoms, such as diarrhea, abdominal pain, or altered bowel habits, for a duration exceeding 6 weeks.
Patients with no prior diagnosis of IBD or IBS.
Patients willing to provide informed consent and comply with study requirements.
Those without recent use of immunosuppressants or anti-inflammatory medications that could affect biomarker levels
Disqualifiers
Patients with a confirmed diagnosis of IBD and currently on treatment.
Those with acute gastroenteritis, infectious colitis, or positive stool cultures for pathogens.
Patients diagnosed with colorectal cancer, celiac disease, or other known organic GI disorders.
Recent antibiotic, NSAID, or corticosteroid use within the past 4 weeks.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
100 Participants
are grouped into 3 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov